RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery

NCT ID: NCT02065375

Last Updated: 2025-06-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 109 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-02-28
• Study Completion Date: 2014-09-30

Brief Summary

This study assesses the efficacy and safety of two concentrations of RTA 408 Ophthalmic Suspension in the treatment of patients who have inflammation and pain following ocular surgery.

Detailed Description

Following ophthalmic surgery, the current standard of care includes a topical ophthalmic corticosteroid or other anti-inflammatory agent to treat ocular inflammation and improve patient comfort. If left untreated, inflammation of the eye may result in further ocular complications including scarring, vision loss, or blindness. Although the exact dosing regimen is physician-dependent, patients are typically prescribed a topical corticosteroid for a period of 2-4 weeks following surgery, being tapered over the course of delivery as the inflammation subsides. Topical anti-inflammatory agents are usually administered multiple times per day, particularly in the early period following ophthalmic surgery. Continuing efforts in drug development aim to identify alternatives to ophthalmic corticosteroid use, due to their well-known local and systemic negative side effects.

Conditions

Inflammation and Pain Following Ocular Surgery

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Omaveloxolone Ophthalmic Suspension 1.0%

Patients will receive a single drop of Omaveloxolone Ophthalmic suspension 1.0% instilled into the study eye twice daily (approximately 12 hours apart) for 14 days, beginning 24 ± 6 hours after surgery

Group Type: EXPERIMENTAL

Omaveloxolone Ophthalmic Suspension 1.0%

Intervention Type: DRUG

Omaveloxolone Ophthalmic Suspension 0.5%

Patients will receive a single drop of Omaveloxolone Ophthalmic suspension 0.5% instilled into the study eye twice daily (approximately 12 hours apart) for 14 days, beginning 24 ± 6 hours after surgery

Group Type: EXPERIMENTAL

Omaveloxolone Opthalmic Suspension 0.5%

Intervention Type: DRUG

Placebo

Patients will receive a single drop of vehicle for Omaveloxolone Ophthalmic suspension was instilled into the study eye twice daily (approximately 12 hours apart) for 14 days, beginning 24 ± 6 hours after surgery

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Interventions

Omaveloxolone Ophthalmic Suspension 1.0%

Intervention Type: DRUG

Omaveloxolone Opthalmic Suspension 0.5%

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Other Intervention Names

RTA 408; RTA 408

Eligibility Criteria

Inclusion Criteria

1. Be greater than or equal to 18 years of age of either sex or any race;

2. Have undergone unilateral cataract extraction via phacoemulsification on the day prior to study enrollment/randomization;

3. Have a grade of ≥2 in anterior chamber cell score on day after surgery (Day 1);

4. Have a potential post-operative pin-hole visual acuity (VA) of greater than 1.0 logarithm of the minimum angle of resolution (logMAR) in the operative eye and fellow eye as measured using an Early Treatment for Diabetic Retinopathy Study (ETDRS) chart;

Exclusion Criteria

1. Have any intraocular inflammation present in the study eye during the screening slit lamp examination;

2. Have a score greater than "0" on the Ocular Pain Assessment at Screening in the study eye;

3. Have an immunosuppressive disease or an autoimmune disease that in the opinion of the Investigator could affect the quality of the ocular surface;

4. Have active or chronic/recurrent ocular or systemic disease that is uncontrolled and will likely affect wound healing;

5. Have an intraocular pressure (IOP) ≤ 5 mmHg in either eye;

6. Require the use of a contact lens or a collagen shield within 72 hours of investigational drug treatment or during the study period in the study eye; be unwilling to discontinue use of contact lenses during study period in the study eye;

7. Require use of non-diagnostic topical ophthalmic solutions (other than perioperative mydriatics, anesthetics and antiseptics, prophylactic antibiotics, lid scrubs for mild blepharitis, or artificial tears for the management of dry eye) in the study eye for the duration of the study;

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

AbbVie

INDUSTRY

Sponsor Role: collaborator

Biogen

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Garden Grove, California, United States

Fort Myers, Florida, United States

Kansas City, Missouri, United States

Elizabeth City, North Carolina, United States

Austin, Texas, United States

Houston, Texas, United States

Countries

United States

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

RTA 408-C-1307

Identifier Type: -

Identifier Source: org_study_id